NEUROBIOLOGICAL TECHNOLOGIES INC

As of September 30, 2009, NEUROBIOLOGICAL TECHNOLOGIES INC carries a market capitalization of 24.24M, placing it among publicly traded companies globally. Its enterprise value stands at -2.00M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of September 30, 2009, NEUROBIOLOGICAL TECHNOLOGIES INC has 26.93M shares outstanding.

As of September 30, 2009, NEUROBIOLOGICAL TECHNOLOGIES INC trades at a trailing price-to-earnings ratio of 2.15. The price-to-sales ratio is 0.84, and the price-to-book ratio stands at 0.84.

As of September 30, 2009, NEUROBIOLOGICAL TECHNOLOGIES INC maintains a current ratio of 45.33, meaning it holds 45.3x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended September 30, 2009, NEUROBIOLOGICAL TECHNOLOGIES INC posted a return on equity (ROE) of 49.23, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 32.67, measuring how efficiently the asset base is converted into earnings. The company generates approximately 1.56M in revenue per employee across its workforce of 18.50, a quick read on workforce productivity versus industry peers.

Over the twelve months ended September 30, 2009, NEUROBIOLOGICAL TECHNOLOGIES INC recorded 96,000.00 in income tax expense.

As of the close on August 21, 2026, NEUROBIOLOGICAL TECHNOLOGIES INC's stock has declined approximately 99.00% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.00.

Over the twelve months ended September 30, 2009, NEUROBIOLOGICAL TECHNOLOGIES INC generated 28.81M in revenue and converted that into 11.29M in net income, yielding earnings per share of 0.42. EBITDA reached 11.95M, while operating income came in at 12.05M.

These figures are as of September 30, 2009. Total book value stands at 28.88M, with working capital of 29.04M providing operational flexibility.

NEUROBIOLOGICAL TECHNOLOGIES INC produced -11.06M in operating cash flow over the twelve months ended September 30, 2009. After subtracting - - in capital expenditures, free cash flow totaled -11.06M - equivalent to -0.41 per share.

These figures cover the twelve months ended September 30, 2009. The operating margin of 41.82 and net profit margin of 39.19 provide insight into operational efficiency.

These figures cover the twelve months ended September 30, 2009. Free cash flow yield is negative at -45.63: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at 0.00, meaning NEUROBIOLOGICAL TECHNOLOGIES INC raised more capital through share issuance and new debt than it returned via dividends and buybacks.

NEUROBIOLOGICAL TECHNOLOGIES INC's most recent stock split took place on September 17, 2007 with a 7:1 split ratio.

As of September 30, 2009, NEUROBIOLOGICAL TECHNOLOGIES INC has an Altman Z-Score of 20.17, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.